INTRODUCTION
============

The duration of dual antiplatelet therapy (DAPT) in the drug-eluting stent (DES) era remains controversial.[@B1] Current clinical practice guidelines recommend the use of DAPT for 6 to 12 months after DES implantation.[@B2] However, in real-world practice, the use of DAPT for more than 12 months, the use of extended DAPT for more than 3 years, and nearly indefinite use of DAPT are common for various reasons. A recent large randomized controlled trial indicated that the use of DAPT beyond 1 year after DES implantation significantly reduced the risk of stent thrombosis (ST) and major adverse events, but increased the risk of bleeding, which was associated with an increase in mortality.[@B3] Therefore, we sought to investigate the major clinical, angiographic, and procedural determinants for extended-DAPT use (DAPT \>3 years), and to compare the long-term clinical outcomes between patients who used DAPT for more than 3 years and those who used DAPT for up to 12 months.

MATERIALS AND METHODS
=====================

Between April 2003 and March 2012, patients who underwent percutaneous coronary intervention (PCI) using DESs and met the study criteria were enrolled in the Korean Multicenter Angioplasty Team registry.[@B4] A total of a 4081 patients were identified for analysis after excluding patients with the following conditions: 1) major adverse events such as death, myocardial infarction (MI), ST, repeated revascularization, stroke, or major bleeding; 2) clinical follow-up duration of \<3 years; and 3) unclear DAPT duration ([Fig. 1](#F1){ref-type="fig"}). Patients were classified into three groups according to DAPT duration after DES implantation as follows: patients who used DAPT for more than 3 years (extended-DAPT group; n=1414); patients who used DAPT for 1--3 years (intermediate-DAPT; n=1394); and patients who discontinued DAPT and switched to single antiplatelet therapy within 12 months according to clinical guidelines (guideline-DAPT group; n=1273). To evaluate the major determinants for long-term outcomes of extended DAPT use, various baseline clinical, angiographic, and procedural characteristics and clinical outcomes of the extended-DAPT group were compared to those of the guideline-DAPT group. To compare the clinical outcomes, a landmark analysis was performed 3 years after the index procedure. In this study, DAPT was defined as the combination of aspirin and clopidogrel, and patients who received other P2Y12 inhibitors were not included. The Institutional Review Board or ethics committee approved the study protocol (4-2018-0759), and all patients provided written informed consent before participating in the study.

Data were recorded using standard case report forms, and procedural angiographies were forwarded to the coordinating center. Baseline clinical and angiographic data were collected for all patients, including age, sex, traditional coronary risk factors, past medical history, and clinical presentation.

Follow-up included visits to the outpatient clinic at 30 days and 3 months after the procedure and every 3 to 6 months thereafter. Patients who were lost to regular clinical follow-up were contacted by telephone and asked about their clinical status.

The primary endpoints were 1) major clinical, angiographic, and procedural determinants for extended-DAPT use (DAPT \>3 years) and 2) the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, MI, ST, and stroke. The secondary endpoints were 1) net adverse clinical events (NACE), defined as the composite of all-cause death, MI, ST, stroke, and major bleeding; 2) the composite of cardiac death, MI, and ST; and 3) individual components of MACCE and NACE.

All events were defined according to the Academic Research Consortium and an expert consensus document that defined the third universal definition for MI.[@B5][@B6] Deaths were classified as being due to cardiac or noncardiac causes.[@B5] MI was defined as a creatine kinase myocardial band fraction elevation above the upper limit of normal (ULN) or troponin T/I \>99th percentile of the ULN, with concomitant ischemic symptoms, electrocardiographic findings, or abnormal imaging findings indicative of myocardial ischemia unrelated to an interventional procedure.[@B5][@B6] ST was defined as definite or probable ST.[@B5] Stroke was defined as brain cell death caused by ischemia based on pathological, imaging, or other objective evidence of cerebral focal ischemic injury in a defined vascular distribution or clinical evidence of cerebral focal ischemic injury based on symptoms persisting ≥24 hours or until death; other etiologies were excluded.[@B7] Strokes were determined to be either hemorrhagic or ischemic using imaging studies. Major bleeding was defined as type 3 or 5 according to the Bleeding Academic Research Consortium criteria.[@B8] Congestive heart failure was defined as left ventricle ejection fraction \<40%.[@B9] Bifurcation lesions were defined as Medina classification (1.1.1), (1.0.1), or (0.1.1) lesions.[@B10] The DAPT scoring system assigned 1 point each for MI at presentation, prior MI or PCI, diabetes, stent diameter \<3 mm, cigarette smoking, and paclitaxel-eluting stent; 2 points each for the history of congestive heart failure/low ejection fraction (\<30%) and vein graft intervention; −1 point for age 65--75 years; and −2 points for age ≥75 years.[@B11]

Continuous variables are expressed as a mean±standard deviation, and categorical data are presented as frequencies. For group comparisons, Pearson\'s chi-square test, Fisher\'s chi-exact test, or Wilcoxon rank-sum test were used, as appropriate. Time-to-event data are presented using Kaplan-Meier estimates. The rates for each event during the follow-up period were analyzed using Kaplan-Meier method. Log-rank test was used to compare survival rates. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated from a Cox proportional hazards model. To identify the determinants for the use of extended-DAPT, we performed univariate and multivariate analyses. Any variable with *p* value\<0.10 in univariate analysis was included in the multivariate models. To reduce bias between the two groups in comparison, propensity score matching was used. Propensity score adjusting was used in the logistic regression models, with DAPT continuation at 36 months used as the dependent variable along with 27 independent variables. A two-sided *p* value\<0.05 was considered statistically significant. Statistical analyses were performed using SPSS statistical software (SPSS version 23.0 for Windows, IBM Corp., Armonk, NY, USA).

RESULTS
=======

Among the eligible patients (n=4081), 1414 (34.6%) were included in the extended-DAPT group and 1273 were included in the guideline-DAPT group ([Fig. 1](#F1){ref-type="fig"}). The baseline clinical characteristics of both groups are presented in [Table 1](#T1){ref-type="table"}. Compared to the guideline-DAPT group, the extended-DAPT group had higher incidences of prior MI, PCI, and bypass surgery; and acute coronary syndrome (ACS); and a lower left ventricular ejection fraction.

Angiographic and procedural characteristics are provided in [Table 2](#T2){ref-type="table"}. Compared to the guideline-DAPT group, the extended-DAPT group had higher proportions of individuals with lesions with multi-vessel disease, in-stent restenosis, bifurcation, and number of lesions treated ≥2. The extended-DAPT group had a greater number of stents implanted, longer- and smaller-sized stents used, and a more frequent use of first-generation DESs compared to the guideline-DAPT group.

DAPT scores were higher in the extended-DAPT group than in the guideline-DAPT group (*p*\<0.01), and the proportion of patients with DAPT scores greater than 2 points was higher in the extended-DAPT group (50.3% vs. 29.3%, *p*\<0.01) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online).

In multivariate analyses for the determinants of extended use of DAPT, ACS presentation was the most significant clinical determinant. Of the angiographic and procedural variables, bifurcation, total stent length ≥28 mm, stent diameter ≤3.0 mm, and use of first-generation DESs were significant determining factors for the extended use of DAPT ([Table 3](#T3){ref-type="table"}).

During follow-up (median duration, 120 months), there were 79 MACCEs (2.9%; 36 all-cause deaths, 29 MI, 6 ST, 22 strokes) after DES implantation, and no significant difference was noted between the extended-DAPT and guideline-DAPT groups in both the crude- and propensity-matched analyses ([Table 4](#T4){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}). The rates of MACCE and NACE were not significantly different between the two groups in either the crude- or propensity-matched analyses. The rates of composite all-cause death, MI, and ST were also not significantly different between the two groups in both the crude- and propensity-matched analyses. The rates of major bleeding were similar between the two groups (*p*=0.185). In propensity-matched analyses, the extended-DAPT group showed a trend toward having a higher major bleeding rate compared to the guideline-DAPT group, although the difference was not statistically significant (*p*=0.070).

We also performed subgroup analyses while focusing on the major determining factors for extended-DAPT ([Fig. 3](#F3){ref-type="fig"}). In the subgroup analyses of composite of all-cause death, MI, and ST, a significant interaction was not noted. In multivariate analysis for the composite of all-cause death, MI, and ST, age (per year) and total stent length ≥28 mm were significant risk factors ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online).

DISCUSSION
==========

The principal findings of the current study are as follows: 1) In real-world practice, extended DAPT is frequently used in patients without MACCE and with DES implantation (approximately 1/3 of patients). 2) Significant determinants for the extended use of DAPT for more than 3 years were ACS, bifurcation, small diameter and long length of DES, and use of first-generation DESs. 3) In patients undergoing PCI, the outcomes after extended-DAPT, defined as indefinite use of DAPT with aspirin and clopidogrel, did not show superiority over those after the guideline-DAPT, and major bleeding rates were similar. 4) In patients treated with first-generation DESs, extended use of DAPT was significantly associated with lower MACCE rates compared to the use of guideline-DAPT.

Antiplatelet treatment is a cornerstone in the management of patients with DES implantation for preventing ST.[@B2] However, even with the designated duration recommended in current guidelines, the optimal DAPT duration after DES implantation still remains debatable.[@B3][@B12][@B13] Both prolonged DAPT for longer than 1 year and short-term DAPT for 3--6 months have been proposed. A recent randomized DAPT trial demonstrated that the use of DAPT beyond 1 year after the placement of a DES significantly reduced the risks of ST (1.4% vs. 0.4%) and MACCE (5.9% vs. 4.3%) compared to using aspirin therapy alone. A previous meta-analysis also indicated that DAPT for 1 year after DES implantation reduced the occurrence of MI and ST, but increased mortality due to an increased risk of non-cardiovascular mortality.[@B14] In the current real-world registry study, 34.6% of patients who had not experienced MACCE for 3 years still received DAPT at 3 years. Similarly, the patterns of nonadherence to antiplatelet regimens in stented patients (PARIS) registry investigating DAPT patterns in post-PCI patients indicated that 42.0% of patients were still receiving DAPT at 2 years.[@B15] Thus, there appear to be some conflict between the guideline recommendations and the actual use in recent clinical trials. In addition, the incidence and determinants for the extended use of DAPT have not been clearly established in real-world practice.

Many scoring systems have been suggested for determining the duration of DAPT.[@B11][@B16][@B17] In particular, DAPT, PARIS, and the Predicting Bleeding Complications In Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score have focused on clinical determinants for the optimal duration of DAPT. In the current study, the proportion of patients with a DAPT score of more than 2 points was significantly higher in the extended-DAPT group, and the initial clinical presentation of ACS was the most significant clinical factor that determined the duration of DAPT. Indeed, previous studies have reported that the use of extended DAPT in ACS patients reduces recurrent ischemic events, and that a significant proportion of patients experience adverse cardiac events beyond the first year after ACS.[@B18]

Lesion- or procedural-complexity could be considered when determining DAPT duration. However, these are not considered in the current scoring systems that are used to determine DAPT duration. In contrast, lesion- and procedural-complexity were identified as major determinants for the use of extended DAPT in this study. Stent-related predictors were also significant determining factors for DAPT duration. In the current study, the total stented length of ≥28 mm, minimal stent diameter of ≤3.0 mm, and the use of first-generation DES were major determining factors. Previous meta-analyses indicated that the most significant predictors of ST include longer stent length \[odds ratio (OR), 1.3; 95% CI, 1.2--1.5, per 10 mm\] and final minimal lumen diameter with stent (OR, 04; 95% CI, 0.2--0.7, per 1 mm).[@B19] Another study on the etiology of very-late ST also indicated that patients with very-late ST had longer lesions and stents.[@B20] Therefore, physicians tend to use extended DAPT. A significant angiographic predictor in this study was the occurrence of a bifurcation lesion. This may have been related to the increasing concerns caused by a higher risk of ST after the use of the two-stent technique or malapposed metal burden in the jailed side branch from the use of a cross-over single stent. A previous study reported that the risk of all-cause death or MI was significantly lower in the ≥12-month DAPT group than in the \<12-month DAPT group after PCI for bifurcation lesions using DES.[@B21]

The type of DES was also a significant determining factor for the extended use of DAPT. Some registry data have indicated a continually increasing risk of ST several years after first-generation DES implantation.[@B22] Currently available registry data suggest a lower rate of ST in patients who received second-generation DESs compared to those who received first-generation DESs.[@B23] In the patients who received first-generation DESs in this study, there was a lower rate of MACCE in the extended-DAPT group compared to the guideline-DAPT group. A previous study (ARTIC-Generation; Clinical Outcome of First- vs. Second-Generation DES According to DAPT Duration) also indicated worse clinical outcomes with first-generation DESs compared to second-generation DESs, a difference that appeared to persist even with prolonged DAPT (6.2% vs. 2.6%; HR, 2.31; 95% CI, 1.31--4.07; *p*=0.004).[@B24] In the current study, extended DAPT use led to a significant reduction in MACCE in patients who were treated with first-generation DESs. Based on the results of this study and other studies, extended DAPT could be carefully considered for patients treated with first-generation DESs.

There are several concerns regarding extended DAPT, such as increased major bleeding \[ARCTIC-Interruption (Dual-Antiplatelet Treatment beyond 1 Year after Drug-Eluting Stent Implantation): 12-month vs. 18--30 month DAPT, \<0.5% vs. 1%, *p*=0.073; DAPT: 12-month vs. 30-month DAPT, 1.6% vs. 2.5%, *p*=0.001; PRODIGY (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study): 24-month vs. 6-month DAPT, 7.4% vs. 3.5%, *p*=0.0002\].[@B3][@B13][@B25]

However, in the current study, extended DAPT did not significantly increase the risk of major bleeding after propensity matching (2.1% vs. 1.2%, *p*=0.07). Therefore, extended DAPT could be used in patients at high thrombotic risk without excessively increasing the risk of major bleeding. In clinical practice, the duration of DAPT may be tailored after careful evaluation of both bleeding and ischemic risk, while taking into consideration the clinical presentation, lesion complexity, and procedural factors.

The strength of this study lies in its use of population-based, real-world registries. However, this study had several limitations. First, this was a retrospective analysis of registry data. Second, since the current study included only patients who did not experience a major event during 3 years after PCI and were compliant with the designated therapy, the study results were only relevant to patients who achieved that milestone. In interpreting the results of the current study, the group of subjects should not be expanded, and the results should be interpreted with caution. Third, neither medication adherence nor tolerability was evaluated. Fourth, as the patients enrolled in this study were event-free for 3 years, there was a possibility that the patients at low risk of bleeding or cardiovascular events were enrolled. Fifth, patients who had used DAPT for \>3 years were classified into the extended-DAPT group, but this classification was arbitrary. Careful attention would be needed for interpretation of the current results. Notwithstanding, 86.4% of the patients in the extended-DAPT group actually used DAPT for more than 5 years. Sixth, the classification of the guideline, intermediate, and extended-DAPT groups may be an arbitrary classification. The guideline-DAPT group was developed for comparison with the extended-DAPT group, and was classified according to the duration of DAPT use. Seventh, we could not achieve perfect matching or control of all of the confounding variables, even though we conducted propensity score matching analysis to reduce bias. However, we were able to exclude all of the extremes in each group. Finally, this study only included thienopyridine P2Y12 inhibitors. Therefore, additional studies comparing the extended DAPT using new antiplatelet agents, such as ticagrelor and prasugrel, with standard DAPT should be performed to further guide clinical practice.

In conclusion, the significant predictors for the use of extended DAPT for more than 3 years were ACS, bifurcation, small stent diameter, long length of DES, and first-generation DES in the real world. In patients undergoing PCI, indefinite use of DAPT did not show superiority in reducing the clinical events compared to the guideline-DAPT. Moreover, major bleeding rates were similar. Notably, however, in patients who were treated with first-generation DESs, extended-DAPT was associated with significantly lower MACCE rates compared to guideline-DAPT.
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SUPPLEMENTARY MATERIALS
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###### Supplementary Table 1

DAPT Score

###### Supplementary Table 2

Univariate and Multivariate Analyses of Determinants for a Composite of All-Cause Death, Myocardial Infarction, and Stent Thrombosis (After propensity score matching)

![Study at a glance. DAPT, dual antiplatelet therapy; MACCE, major adverse cardiovascular and cerebrovascular events.](ymj-61-597-g001){#F1}

![Cumulative MACCE rates according to Kaplan-Meier analyses. (A) Crude-analysis. (B) Propensity score matching analysis. DAPT, dual antiplatelet therapy; MACCE, major adverse cardiovascular and cerebrovascular events.](ymj-61-597-g002){#F2}

![Subgroup analyses. HRs for NACE from Cox regression models investigating extended-DAPT versus guideline-DAPT are shown for patient subgroups. DAPT, dual antiplatelet therapy; HR, hazard ratio; CI, confidence interval; NACE, net adverse clinical events.](ymj-61-597-g003){#F3}

###### Clinical Characteristics
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  Characteristics                                                   Extended-DAPT (n=1414)   Guideline-DAPT (n=1273)   *p* value
  ----------------------------------------------------------------- ------------------------ ------------------------- -----------
  Age (yr)                                                          62.8±9.8                 62.7±9.9                  0.809
  Male                                                              927 (66)                 858 (67)                  0.456
  Body mass index (kg/m^2^)                                         24.8±3.0                 24.8±2.9                  0.950
  Current smoker                                                    308 (22)                 301 (24)                  0.249
  Dyslipidemia or statin use before procedure                       1160 (82)                1057 (83)                 0.498
  Hypertension                                                      879 (62)                 808 (64)                  0.484
  Diabetes mellitus                                                 447 (32)                 387 (30)                  0.498
  Chronic kidney disease                                            39 (3)                   23 (2)                    0.101
  Congestive heart failure                                          38 (3)                   27 (2)                    0.340
  Left ventricular ejection fraction (%)                            57.8±13.4                61.4±12.3                 \<0.001
  Prior stroke                                                      116 (8)                  107 (8)                   0.850
  Prior myocardial infarction                                       157 (11)                 71 (6)                    \<0.001
  Previous percutaneous coronary intervention                       265 (19)                 136 (11)                  \<0.001
  Prior bypass surgery                                              59 (4)                   35 (3)                    0.045
  Clinical presentation                                                                                                \<0.001
   Acute coronary syndrome                                          652 (46)                 492 (39)                  
    Acute myocardial infarction                                     301 (21)                 249 (20)                  
    Unstable angina                                                 351 (25)                 243 (19)                  
   Stable angina                                                    762 (54)                 781 (61)                  
  Medications at discharge                                                                                             
   β-blockers                                                       849 (60)                 741 (58)                  0.330
   Angiotensin-converting enzyme or angiotensin-receptor blockers   789 (56)                 724 (57)                  0.583
   Statin                                                           1376 (97)                1235 (97)                 0.642

DAPT, dual antiplatelet therapy.

Data are presented as the mean±SD or percentage (%).

###### Angiographic and Procedural Characteristics
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  Characteristics                                  Extended-DAPT (n=1414)   Guideline-DAPT (n=1273)   *p* value
  ------------------------------------------------ ------------------------ ------------------------- -----------
  Multi-vessel (2- or 3-vessel) disease            980 (69)                 742 (58)                  \<0.001
  Treated vessel                                                                                      0.596
   Left anterior descending                        813 (58)                 761 (60)                  
   Left circumflex                                 227 (16)                 184 (15)                  
   Right coronary                                  365 (26)                 320 (25)                  
   Graft                                           9 (1)                    8 (1)                     
  Left main artery involvement                     121 (9)                  112 (9)                   0.825
  Chronic total occlusion                          71 (6)                   57 (5)                    0.243
  In-stent restenosis                              69 (9)                   30 (3)                    \<0.001
  Bifurcation                                      385 (50)                 366 (36)                  \<0.001
  Calcification (moderate or severe)               131 (11)                 127 (11)                  0.853
  Number of lesions treated ≥2                     549 (39)                 345 (27)                  \<0.001
  Total number of stents implanted                 1.6±0.7                  1.5±0.6                   \<0.001
  Total stent length                               40.5±21.3                32.8±17.6                 \<0.001
  Total stent length                               ≥28 mm 968 (69)          675 (53)                  \<0.001
  Stent diameter                                   3.0±0.4                  3.1±0.4                   \<0.001
  Stent diameter ≤3.0 mm                           1106 (78)                571 (45)                  \<0.001
  Type of drug-eluting stents                                                                         \<0.001
   First-generation                                1078 (76)                313 (25)                  \<0.001
    Sirolimus-eluting                              762                      256                       
    Paclitaxel-eluting                             316                      57                        
   Second-generation                               269 (19)                 932 (73)                  
    Everolimus-eluting                             5                        288                       
    Zotarolimus-eluting                            199                      379                       
    Biolimus-eluting                               15                       265                       
   Mixed use of the first- and second-generation   67 (5)                   28 (2)                    
  Glycoprotein IIB/IIIA blocker use                21 (4)                   20 (3)                    0.391

DAPT, dual antiplatelet therapy.

Data are presented as the mean±SD or percentage (%).

###### Univariate and Multivariate Analyses of Determinants for the Extended Use of DAPT
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  Variables                                   Univariate analysis OR (95% CI)   *p* value   Multivariate analysis^\*^   
  ------------------------------------------- --------------------------------- ----------- --------------------------- ---------
  Clinical variables                                                                                                    
   Age (yr)                                   1.00 (0.99--1.01)                 0.809       1.00 (0.98--1.01)           0.462
   Body mass index (kg/m^2^)                  1.01 (0.97--1.03)                 0.950                                   
   Male                                       1.06 (0.90--1.25)                 0.456       1.26 (0.95--1.67)           0.114
   Hypertension                               0.95 (0.81--1.11)                 0.484                                   
   Diabetes mellitus                          1.06 (0.90--1.25)                 0.498                                   
   Chronic kidney disease                     1.54 (0.92--2.60)                 0.103                                   
   Current smoker                             0.90 (0.75---1.08)                0.250                                   
   Acute coronary syndrome presentation       1.38 (1.18--1.61)                 \<0.001     1.37 (1.06--1.79)           0.018
   Prior percutaneous coronary intervention   1.93 (1.54--2.41)                 \<0.001     1.43 (0.92--2.21)           0.113
   Prior bypass surgery                       1.54 (1.01--2.36)                 0.047       1.22 (0.59--2.53)           0.598
   Prior myocardial infarction                2.12 (1.58--2.83)                 \<0.001     1.55 (0.96--2.49)           0.072
   Prior heart failure                        1.27 (0.77--2.10)                 0.341                                   
   Prior stroke                               0.97 (0.74--1.28)                 0.850                                   
  Angiographic variables                                                                                                
   Treated lesion number ≥2                   1.71 (1.45--2.01)                 \<0.001     0.91 (0.65--1.30)           0.613
   Multivessel disease                        1.62 (1.38--1.89)                 \<0.001     1.16 (0.85--1.58)           0.345
   Left main involvement                      0.97 (0.74--1.27)                 0.825                                   
   In-stent restenosis                        3.38 (2.18--5.24)                 \<0.010     2.04 (0.99--4.20)           0.053
   Bifurcation                                1.78 (1.47--2.15)                 \<0.001     1.55 (1.19--2.02)           0.001
   Chronic total occlusion                    1.24 (0.87--1.77)                 0.244                                   
  Procedural variables                                                                                                  
   Total stent length ≥28 mm                  1.92 (1.64--2.25)                 \<0.001     1.54 (1.12--2.12)           0.007
   Stent diameter ≤3.0 mm                     4.42 (3.73--5.22)                 \<0.001     3.33 (2.51--4.43)           \<0.001
   First-generation drug-eluting stents       11.91 (9.93--14.29)               \<0.001     11.43 (8.78--14.87)         \<0.001

DAPT, dual antiplatelet therapy; OR, odds ratio; CI, confidence interval.

^\*^Any variable with *p*\<0.10 in univariate analysis was included in the multivariate models.

###### Clinical Outcomes at 10 Years (Median Follow-Up Duration)
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  Crude analysis                                               Extended-DAPT (n=1414)   Guideline-DAPT (n=1273)   HR (95% CI)         *p* value
  ------------------------------------------------------------ ------------------------ ------------------------- ------------------- -----------
  Follow-up duration (month)                                   111.11±18.8              103.0±18.0                                    
  MACCE (all-cause death, MI, ST, and stroke)                  44 (3.3)                 35 (3.2)                  1.08 (0.69--1.68)   0.739
  NACE (all-cause death, MI, ST, stroke, and major bleeding)   60 (4.7)                 43 (4.4)                  1.10 (0.74--1.64)   0.629
  Composite of all-cause death, MI, and ST                     32 (2.4)                 30 (2.8)                  0.91 (0.55--1.49)   0.700
  Death                                                        22 (1.7)                 14 (1.4)                  1.31 (0.67--2.56)   0.434
   Cardiovascular death                                        2 (0.1)                  4 (0.4)                   0.41 (0.07--2.24)   0.303
   Non-cardiovascular death                                    20 (1.5)                 10 (1.0)                  1.67 (0.78--3.58)   0.186
  MI                                                           14 (1.1)                 15 (1.3)                  0.80 (0.39--1.66)   0.553
  ST                                                           3 (0.2)                  3 (0.3)                   0.84 (0.17--4.19)   0.832
  Total stroke                                                 13 (1.0)                 9 (0.8)                   1.25 (0.53--2.92)   0.611
   Ischemic stroke                                             11 (0.8)                 8 (0.7)                   1.18 (0.47--2.94)   0.726
   Hemorrhagic stoke                                           2 (0.1)                  3 (0.3)                   0.60 (0.10--3.56)   0.569
  Major bleeding                                               19 (1.5)                 9 (1.2)                   1.71 (0.77--3.80)   0.185

  Propensity score matching analysis                           Extended DAPT (n=677)   Guideline DAPT (n=1149)   HR (95% CI)         *p* value
  ------------------------------------------------------------ ----------------------- ------------------------- ------------------- -----------
  Follow-up duration, months                                   108.4±21.7              102.8±18.4                                    
  MACCE (all-cause death, MI, ST, and stroke)                  24 (3.8)                33 (3.2)                  1.22 (0.72--2.07)   0.453
  NACE (all-cause death, MI, ST, stroke, and major bleeding)   36 (6.1)                39 (4.2)                  1.43 (0.90--2.25)   0.128
  Composite of all-cause death, MI, and ST                     16 (2.5)                28 (2.8)                  0.96 (0.52--1.78)   0.895
  Death                                                        12 (1.9)                13 (1.3)                  1.51 (0.69--3.31)   0.306
   Cardiovascular death                                        1 (0.2)                 4 (0.5)                   0.39 (0.04--3.52)   0.402
   Non-cardiovascular death                                    11 (1.8)                9 (0.8)                   2.02 (0.84--4.88)   0.119
  MI                                                           7 (1.1)                 14 (1.4)                  0.84 (0.34--2.09)   0.713
  ST                                                           2 (0.3)                 3 (0.3)                   1.07 (0.18--6.42)   0.944
  Total stroke                                                 8 (1.3)                 8 (0.8)                   1.64 (0.61--4.39)   0.324
   Ischemic stroke                                             8 (1.3)                 8 (0.8)                   1.64 (0.61--4.39)   0.324
   Hemorrhagic stoke                                           0                       0                         \-                  \-
  Major bleeding                                               12 (2.1)                8 (1.2)                   2.29 (0.93--5.63)   0.070

DAPT, dual antiplatelet therapy; HR, hazard ratio; CI, confidence interval; MACCE, major adverse cardiovascular and cerebrovascular events; NACE, net adverse clinical events; MI, myocardial infarction; ST, stent thrombosis.

Data are presented as the mean±SD or number (%) and percentages, along with Kaplan-Meier estimates.
